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Abstract
As the coronavirus disease 2019 pandemic spreads around the globe, access to radiation therapy remains critical for patients with cancer.
The priority for all radiation oncology departments is to protect the staff and to maintain operations in providing access to those patients
requiring radiation therapy services. Patients with tumors of the aerodigestive tract and pelvis, among others, often experience toxicity
during treatment, and there is a baseline risk that adverse effects may require hospital-based management. Routine care during weekly
visits is important to guide patients through treatment and to mitigate against the need for hospitalization. Nevertheless, hospitalizations
occur and there is a risk of nosocomial severe acute respiratory syndrome coronavirus-2 spread. During the coronavirus disease 2019
pandemic, typical resources used to help manage patients, such as dental services, interventional radiology, rehabilitation, and others are
limited or not at all available. Recognizing the need to provide access to treatment and the anticipated toxicity of such treatment, we
have developed and implemented guidelines for clinical care management with the hope of avoiding added risk to our patients. If
successful, these concepts may be integrated into our care directives in nonpandemic times.
 2020 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
In December 2019, cases of pneumonia of unknown
etiology were first reported in Wuhan City, Hubei Prov-
ince of China.1 These cases have since been linked to a
novel enveloped RNA beta coronavirus named severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-
2),2 which causes the associated coronavirus disease 2019
(COVID-19). COVID-19 has caused a global pandemic,
resulting in considerable morbidity, mortality, and health
care resource strain.3 As of April 11, 2020, 10:00AM
central European time, 1,610,909 global cases of COVID-
19 and 99,690 global deaths had been reported to the
World Health Organization.4 The New York metropolitan
area has been one of the most severely affected regions,
with 160,349 confirmed cases and 8078 deaths thus far
within New York City and surrounding Nassau, Suffolk,
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and Westchester counties, accounting for 30% of U.S.
cases and 38% of U.S. deaths.5
Our institution, Northwell Health, is the largest health
care provider in New York State and is based in the
aforementioned counties. Most of our hospitals have
similarly seen a surge of COVID-19 cases, and
throughout our health system, all non-emergent surgeries
and procedures have temporarily been cancelled to pro-
vide capacity for COVID-19erelated hospital admissions.
Early data from Asia and Europe showed an increased
rate of SARS-CoV-2 infection and COVID-19 morbidity
among patients with cancer.6-12 In an effort to reduce
exposure to patients with cancer and conserve health
system resources, oncology societies and institutions have
crafted working guidelines regarding cancer treatments.13-
17 However, the majority of cancer cases require timely
treatment, and we continue to provide curative and
palliative treatments to hundreds of patients daily
throughout the Northwell Health Cancer Institute.
Radiation oncologists are well aware that several dis-
ease sites, such as head and neck, result in high unan-
ticipated hospital admission rates during or soon after
radiation therapy.18,19 As a department, we decided that
we must intensify our current on-treatment care protocols
to ensure timely completion of therapy and drastically
reduce the chance of complications requiring hospital
admission. Therefore, the faculty developed consensus-
driven, experience-based guidelines for intensive on-
treatment management for disease sites that often
require concurrent radiation and chemotherapy for cura-
tive treatment and historically have higher rates of
emergency department (ED) or hospital usage. In this
report, we outline our departmental disease-site specific
guidelines to reduce hospitalization rates during the
COVID-19 pandemic.
Methods
Quality and safety are critically important to the de-
livery of radiation therapy and are cornerstones of our
previously reported Smarter Radiation Oncology pro-
gram.20,21 As part of our departmental culture, new pa-
tient radiation cases are peer-reviewed in prospective
daily contouring rounds before treatment planning be-
gins.22,23 Our departmental quality assurance program
also tracks data on patient hospitalization and discontin-
uation of radiation therapy.24
In March 2020, as the effect of the COVID-19
pandemic upon our health system intensified, we estab-
lished 2 overriding principles: (1) to maintain the safety of
all staff and (2) to maintain access for those patients
requiring radiation therapy services.
First, as care providers from radiation medicine and other
departments were being redeployed throughout the health
system to help manage the pandemic, we purposefully
sought to decrease staff density and machine utilization,
thereby decreasing staff and patient exposure to and risk of
SARS-CoV-2 infection. A priority level was assigned to
each case to determine which patients might safely avoid
treatment or have treatment deferred, attempting to balance
the risk of SARS-CoV-2 infection versus potential adverse
outcomes of deferring treatments. Faculty met virtually on 2
separate occasions to prospectively determine the urgency
and priority of all pending cases, including pending simu-
lations and treatment starts.Group consensuswas required to
assign each patient’s priority.
Second, there was a desire from providers and patients
to minimize SARS-CoV-2 exposure by limiting evalua-
tion or interventions within the ED or hospital, where
possible. To that end, additional management of adverse
events during outpatient treatments should be carried out
within the ambulatory radiation medicine clinic or the
patient’s home. Given the hospital strain during the
pandemic, resource availability for nonemergent proced-
ures was also limited. This included, but was not limited
to, operating room availability for cancer surgery,
percutaneous endoscopic gastrostomy placement, esoph-
ageal dilation/stent placement, dental evaluation and
extraction, infusion services, physical and occupational
therapy, and home care services. Management of adverse
effects would therefore need to be more proactive than
reactive and require more intensive management by fewer
care providers.
Therefore, our goals required that we create a frame-
work for clinical practice and resource management that
may be applied to the current and future resource-
constrained settings. Key questions included:
1. Who benefits from increased support during treat-
ment (health system resource utilization)?
2. What health system resources and/or services may
be limited or unavailable?
3. How can we provide intensified support to reduce
hospitalization rates and prevent strain on other
departments?
4. When should interventions be implemented to
reduce the severity of adverse treatment effects?
To address these questions and create a consensus
guideline, a team of physicians, advanced care providers,
and administrators within our radiation medicine service
line convened to review pertinent literature and practice
guidelines to establish recommendations for management
of patients undergoing radiation treatments during this
pandemic.
Results and Recommendations
As of April 10, 2020, there were 3402 COVID-19
inpatients within the 23 hospitals of the health care
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system, 27% of whom were being managed within an
intensive care unit setting and 821 on ventilators. All
available space in the hospitals such as postanesthesia
care units, endoscopy suites, labor and delivery rooms, as
well as auditoriums and lobbies have been converted to
intensive care units or COVID wards.
Prioritization of cases
A tiered system of prioritization (Table 1) was devel-
oped and used to stagger radiation starts and purposefully
reduce machine treatment volume. We classified cases as
those in which patients need treatment immediately, within
30 days, or may be delayed beyond 30 days. As a result, we
reduced the volume of patients on treatment within radia-
tion medicine to approximately 70% of usual capacity.
Of the 307 cases identified and discussed among the
faculty, 188 (61%) were classified priority 1, 84 (27%)
were priority 2, and 35 (11%) were priority 3. Among the
188 priority 1, 36 were head and neck, 26 were lung, 22
were gynecologic, 19 were brain, 17 were gastrointestinal,
and 34 were bone metastases (Table 2). The majority of
cases in priority 1 were curative-intent, treated with
concurrent chemoradiation. These treatments are often
associated with moderate to significant adverse treatment
effects.
Guidelines for pretreatment considerations and
on-treatment management
Table 3 summarizes the guidelines we created to help
manage potential adverse events based on disease site
and/or treatment.25-30 It is important to note that these
recommendations apply only to patients who are not
positive for SARS-CoV-2 and are not symptomatic from
COVID-19.
Discussion
The global COVID-19 pandemic has caused consid-
erable health system strain as a result of dramatically
higher inpatient admissions and illness among clinical
staff.30 Clinical practices have had to adapt quickly to
meet demands for inpatient care while maintaining the
safety of staff and noninfected patients. The vast majority
of oncology treatments must proceed in a timely fashion.
At Northwell Health, we are caring for many of the New
Table 1 Prioritization of radiation treatment start date based on treatment indication
Priority Description Example cases
Priority I Cases where a delay of treatment may result in a loss of life,
progression of disease, or a permanent loss of neurologic or
other function
1. Oncologic emergencies




These patients are to be assessed and managed accordingly.
Priority II Cases that may be delayed for up to 4 weeks, and delay in
treatment is unlikely to result in a loss of life or negatively
affect a patient’s prognosis
1. Early stage head and neck
2. Early stage lung
3. Lymphoma
4. Brain SRS of benign diseasesIf a patient’s treatment is deferred, waiting lists should be
created for priority II patients requiring treatment. These
waiting lists will be reviewed at least weekly depending on
the overall situation and the availability of treatment slots.
Priority III Cases that may be delayed for 30 days or more, where such
delay in radiation treatment is unlikely to result in a loss of
life or negatively affect a patient’s prognosis.
1. Early stage prostate
2. Early stage breast
3. Prostate on androgen deprivation
If a patient’s treatment is deferred, waiting lists should be
created for priority III patients requiring treatment. These
waiting lists will be reviewed for pending treatment
accordingly and the patients contacted for follow-up as
needed.
Abbreviation: SRS Z stereotactic radiosurgery.
Table 2 Patient characteristics
Characteristics No. of patients (n Z 307) %










Priority II 84 27.4
Priority III 35 11.4
Advances in Radiation Oncology: JulyeAugust 2020 Reducing hospitalization rates during COVID-19 623
Table 3 Consensus guidelines for intensive treatment management to reduce hospitalization and adverse events
Disease site Pretreatment Acute CTCAE25 to
manage
Suggested interventions
Anal cancer Health system resources potentially
unavailable:







 Twice weekly OTV after second wk
 Early use of: Silvadene, sitz baths, anti-
diarrheal, pain medication/management
 CBC monitoring, weekly MedOnc visits
(neutropenia/anemia)
 Consider treatment break*
Rectal cancer e
advanced, low-lying
Consider induction chemotherapy as
part of total neoadjuvant therapy to





 Twice weekly OTV after third wk
 Early use of: Silvadene, sitz baths, anti-
diarrheal, pain medication/management
 CBC monitoring, weekly MedOnc visits
Esophageal cancer e
advanced
Health system resources potentially
unavailable:
 Nonemergent procedures
(eg, esophageal dilation, stent
placement, feeding tube placement)







 Twice weekly OTV after second wk
 Early use of: PPI twice daily, oral ste-




 IV fluid hydration by MedOnc
 If MedOnc unavailable, IV fluid hy-
dration within RadMed department
 NG-tube placement (may be difficult,




(particularly for small cell)
Consider deferring adjuvant RT start
date for: consolidative







 Evaluate for O2 need (nocturnal, ambula-
tory, at rest)
 Twice weekly OTV after second wk
 Early use of: oral steroids, PPI, Carafate,
pain medications, nutritional supplement
shakes
 Aggressive management of esophagitis:
PPI twice daily, gabapentin, dietary
evaluation
Head and neck cancers Health system resources
potentially unavailable:
 Dental evaluation
 Feeding tube placement
 Speech/swallow evaluation
 Home care/wound care services
Consider weekly cisplatin dosing for fit
candidates (30-40 mg/m2) instead of
bolus cisplatin.
If borderline candidate for systemic
therapy, do not use. Consider altered
fractionation to compensate for lack of
systemic therapy.
For elderly patients, consider hypo-








 Twice weekly OTV
 Review CBC taken by MedOnc weekly
 Early use of: pain medication/manage-
ment, gabapentin, mouth rinses, nutri-
tional supplement shakes, dietary
evaluation
Hospital avoidance
 When dysphagia begins, start IV fluid
hydration by MedOnc (otherwise fluid
bolus via PEG if available) twice weekly
during chemoradiation
 If MedOnc unavailable, consider IV
fluid hydration within RadMed
department
 NG-tube placement if weight loss
otherwise meeting criteria for PEG
placement
 Low threshold to stop chemotherapy if
patient develops CTCAE  3
 Consider treatment break for refractory
grade 3 symptoms (<1 wk)





 Twice weekly OTV after second wk
(continued on next page)
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York region COVID-19 cases and have had to quickly
adjust our oncology patient management to keep our pa-
tients and staff safe and reduce hospital utilization. Our
multicenter radiation department spans across teaching
and community hospitals as well as outpatient centers.
The current pandemic is having a profound effect on
health care resources, thereby changing the routine prac-
tice of cancer treatments. The multidisciplinary aspect of
cancer caredincluding but not limited to surgical
oncology, medical oncology, radiation oncology, diag-
nostic radiology, pathology, clinical trials, genetic testing,
social work, anesthesia, nutrition, occupational and
physical therapy, pain and palliative caredis significantly
limited based on the needs for care of patients with
COVID-19. What was routine as recently as 4 weeks ago
has been transformed radically.
Fortunately, we have been able to continue providing
patients advanced, high-quality radiation therapy and for
the most part, concurrent chemotherapy. Despite social
distancing, use of telehealth, conversion to shorter frac-
tionation schedules, and deferment of some treatments,
there are numerous patient touchpoints with the radiation
care team. By nature of radiation treatments, patients are
physically present within the department and interacting
with team members often on a daily basis. Especially as
other members of the patient’s multidisciplinary care team
reduce in-person interactions, the radiation care team has
become the main point of interaction. This proximity
should be leveraged to aggressively and pre-emptively
manage patients during treatment.
Rates of unplanned acute hospital encounters during or
soon after radiation therapy may differ across cancer di-
agnoses, but have been reported between 20% to 36%,
with approximately half of acute encounters in the ED and
half inpatient admissions.18,31,32 National policy initia-
tives have aimed to reduce acute hospital encounters
among cancer patients through improved care coordina-
tion.33-36 The importance of these initiatives are under-
scored during this crisis.
Given the effect of treatment delay or morbidity upon
prognosis, a broader macro view of health care outcomes
during this pandemic recognizes that changes in routine
care need to be usurped by a need for intense clinical
management of patients with cancer to avoid complica-
tions that may require ED visits or hospitalizations.
Therefore, as a faculty, we decided that a proactive,
intensive approach to on-treatment management of at-risk
patients was necessary to maintain excellent disease out-
comes while avoiding health system strain. We developed
these guidelines using our combined experience, knowl-
edge of the literature, and consensus. We have imple-
mented these on-treatment guidelines in our clinics
beginning April 13, 2020.
We expect that these clinical guidelines, which advo-
cate for more intensive on-treatment management, will
reduce rates of hospitalization and treatment breaks. We
recognize that these recommendations represent a
resource shift in the department toward more hands-on
clinical care while one is otherwise trying to limit excess
patient-facing care during the COVID-19 pandemic. By
Table 3 (continued )







 Steroid management, perhaps more antiepi-
leptic use than normal
Hospital avoidance
 If progressive neurologic symptoms,
consider outpatient MRI, evaluation by
neuro-oncology/neurosurgery
Vulvar cancer Health system resources potentially
unavailable:
 Decreased OR availability /
increased utilization of definitive
chemoradiation







 Twice weekly OTV after 2nd week
 Early use of: Silvadene, sitz bath, pain
medication/management, antidiarrheal
 CBC monitoring, urinalysis, weekly
MedOnc visits
 Consider treatment break (goal < 1 wk)
Abbreviations: CBC Z complete blood count; CTCAE Z Common Terminology Criteria for Adverse Events; EGJ Z esophagogastric junction; IV
Z intravenous; MRI Z magnetic resonance imaging; NCCNZ National Comprehensive Cancer Network; NG Z nasogastric; NSCLC Z nonsmall
cell lung cancer; OR Z operating room; OTV Z on-treatment visit; PCI Z prophylactic cranial irradiation; PEG Z percutaneous endoscopic
gastrostomy; PPI Z proton-pump inhibitor; RT Z radiation therapy; SCLC Z small cell lung cancer.
* Radiation Therapy Oncology Group (RTOG) 98-1126 allowed 10 day break as needed; in RTOG 0529,27 breaks were mostly due to
neutropenia.
y Total neoadjuvant therapy approach added to 2015 version of NCCN guidelines as an acceptable option.28
z Perioperative chemotherapy is an alternative option to chemoradiation for distal esophagus and EGJ.29,30
Advances in Radiation Oncology: JulyeAugust 2020 Reducing hospitalization rates during COVID-19 625
establishing a prioritization system to defer some patients,
we have counterbalanced the volume of interactions
throughout the department on any given day. Thus, the
new management recommendations should not over-
burden what is an otherwise busy and packed clinical
space.
Conclusions
The COVID-19 global pandemic has had a dramatic
effect on New York area hospitals and practices. North-
well Health is currently managing thousands of New
York’s inpatient cases, and elective procedures are on
hold until the regional rates of infection slow consider-
ably. In this resource-constrained environment, we must
adapt our management of radiation patients to reduce their
risk of hospitalization. Our faculty convened to set pri-
orities for patient treatment and to develop consensus
guidelines for intensive on-treatment management of at-
risk disease sites, typically in patients undergoing
curative-intent radiation therapy with concomitant
chemotherapy. We believe these experience-driven and
consensus-based guidelines will reduce adverse events
that require ED usage and hospitalization among radiation
medicine patients.
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